The AI-powered drug discovery boom continues to heat up, and this time, the momentum has officially shifted to the trillion-dollar weight-loss market.

 

Over the past weekend, Insilico Medicine and Eli Lilly announced another collaboration, a move widely seen as a major bellwether for the industry. Although the joint statement did not specify the exact indications of the candidate molecule, industry insiders speculate that the drug, discovered using Insilico’s PharmaAI platform, is likely an oral GLP-1R targeting therapy for weight loss.

 

This area represents the most promising frontier in global obesity drug development. It also signals that Eli Lilly, a global leader in weight-loss drugs, has once again “voted” with its partnership to endorse the R&D capabilities of China’s AI-driven pharmaceutical industry.

 

Around the same time, Sihuan Pharmaceutical, which has achieved notable success in the medical aesthetics field, announced on April 1 a partnership with Biocytogen to officially enter the weight-loss drug R&D space. Unlike conventional approaches, the collaboration will focus on developing innovative drugs that enable weight loss while maintaining or even increasing muscle mass. AI technology has been explicitly positioned as a core driver of this partnership.

 

These two major collaborations landing in quick succession are no coincidence. They reflect both the intense global competition in the weight-loss drug space and the growing international recognition of China’s AI-powered pharmaceutical capabilities, as well as the proactive efforts of domestic players to secure leading positions in this frontier field.

 

01、 What Are the Advantages of AI + Weight-Loss Drugs?

 

GLP-1 class drugs have ushered in a new era of weight-loss treatment and triggered a wave of global pharmaceutical investment. However, the industry remains constrained by three major bottlenecks, and traditional R&D pathways have progressed slowly.

 

First, limited efficacy. Obesity is a complex metabolic disorder involving multiple systems. Most existing drugs target only one or two pathways. Their weight-loss effects are often difficult to sustain, rebound is common, and muscle loss frequently occurs, trapping patients in a cycle of “lose weight – regain weight.”

 

Second, prominent safety risks. Weight-loss drugs require long-term use. Frequent issues such as gastrointestinal reactions and cardiovascular risks pose considerable challenges to clinical development.

 

Under the dual pressures of efficacy and safety, compounded by high R&D costs and significant failure risks, AI technology has become widely recognized as the key to breaking through these barriers. AI can efficiently discover and design novel molecules with multi-target, multi-pathway synergistic effects. It can also accurately predict efficacy and safety early in the process, addressing the shortcomings of traditional R&D from the outset.

 

This trend is increasingly evident as multinational pharmaceutical companies continue to forge partnerships with Chinese AI-powered drug discovery platforms.

As a global leader in weight-loss therapeutics, Eli Lilly’s strategic moves are particularly telling. Its renewed collaboration with Insilico Medicine reflects the differentiated potential of a preclinical asset. According to Insilico, the candidate has the potential to be administered once weekly—overcoming the limitations of current daily formulations—while achieving weight-loss efficacy comparable to or even surpassing existing marketed products.

 

This asset was discovered using Insilico’s PharmaAI platform. Although the company has not disclosed further development details, its pipeline has progressively demonstrated the value of AI in accelerating drug discovery.

 

To date, Insilico has built a pipeline of three weight-loss drug candidates. Among them, ISM0676, an oral small-molecule GIPR antagonist, achieved a 31.3% body weight reduction in preclinical obesity models when combined with semaglutide. It has the potential to address key pain points of GLP-1 drugs, such as post-withdrawal rebound and muscle loss. The program was empowered by Insilico’s generative AI engines, including Chemistry42 and Alchemistry. From project initiation to nomination of a preclinical candidate (PCC), the process took just 14 months, with fewer than 200 molecules synthesized and tested.

 

Given that weight-loss drugs are among the hottest R&D fields today, leveraging AI to gain a first-mover advantage in both R&D and the market has become an industry consensus.

Sihuan Pharmaceutical’s strategy follows the same logic. Its partnership with Biocytogen to develop weight-loss drugs is driven by a belief in the central role of AI in R&D. In its announcement, the company explicitly stated that the deep integration of AI and automation into antibody drug development is an inevitable industry trend. The “AI + high-throughput” model can significantly shorten R&D timelines, reduce costs, and accelerate the design and screening of first-in-class (FIC) global first-in-class drugs.

 

Through this model, Sihuan will focus on next-generation weight-loss drugs that aim to achieve efficient weight loss by increasing energy expenditure via novel mechanisms of action, while also preserving or improving muscle mass—directly addressing the industry-wide challenge of muscle loss associated with traditional weight-loss drugs.

 

 

02、Chinese Pharma Companies Accelerate Toward Launch

 

Overall, in the field of AI-empowered weight-loss drug development, Chinese pharmaceutical companies have formed a cluster of competitive advantages, with multiple innovative drugs just one step away from commercialization.

 

In January of this year, MDR-001, an AI-discovered innovative drug independently developed by DrugR&D Intelligence, officially entered Phase III clinical trials. It became the first AI-designed weight-loss drug in China to reach this critical stage, potentially representing a major breakthrough in global weight-loss therapeutics.

 

Under traditional R&D models, a Class 1 innovative drug typically takes 7–9 years to advance to Phase III. MDR-001 took only four and a half years—a dramatic improvement in R&D efficiency driven by AI.

 

Clinical data also demonstrate strong competitiveness. Phase IIb results released in June 2025 showed that among 317 participants with an average baseline body weight of approximately 90 kg, the average weight loss after 24 weeks of treatment was 10.3%, demonstrating a clear and meaningful effect.

 

On safety, the results were particularly impressive. No drug-related serious adverse events occurred during the trial. The discontinuation rate due to adverse reactions was only 0.8%, and no clinical risks such as increased heart rate were observed. Tolerability was excellent.

 

Based on current R&D progress, MDR-001 is expected to receive market approval by the end of 2028 or in 2029. It could become the first commercially available AI-designed weight-loss drug in China, capturing a significant first-mover advantage.

 

Also in January, CSPC Pharmaceutical Group announced a landmark partnership with AstraZeneca valued at US$18.5 billion. The core focus of the collaboration is a long-acting peptide weight-loss drug developed using CSPC’s proprietary sustained-release drug delivery platform and AI peptide discovery platform.

 

CSPC’s long-acting technology can extend the dosing interval to once monthly or even longer. The formulation is ready to use and supports self-administration by patients, which could greatly improve long-term treatment adherence. One of the licensed assets, SYH2082, a once-monthly injectable GLP-1/GIP receptor dual-biased agonist long-acting peptide, reflects this approach. The AI discovery platform efficiently completes molecular design and optimization, significantly compressing the early-stage R&D timeline.

 

Looking across the industry, Chinese pharmaceutical companies continue to demonstrate strong competitive advantages: AI enables significantly shorter R&D cycles and lower costs, offering exceptional innovation efficiency and cost competitiveness; precise targeting of unmet clinical needs creates differentiated pipelines that avoid homogeneous competition; and China’s complete pharmaceutical industry chain, combined with a vast unmet market demand, continues to accelerate commercialization. According to J.P. Morgan, the cost of developing an innovative drug pipeline of comparable quality in China is only 30–40% of that in the United States.

 

As multiple AI-driven weight-loss drugs advance into late-stage clinical development, China is assuming an increasingly important role in the global innovative weight-loss drug arena. In this AI-powered race to develop next-generation obesity treatments, Chinese pharmaceutical companies have demonstrated clear technological capabilities and well-structured pipelines.

 

In the coming years, more AI-empowered weight-loss drugs will receive market approval. These therapies will not only provide safer, more effective, and more convenient treatment options for obese patients worldwide but will also propel China’s AI-powered pharmaceutical industry onto the global center stage. As Chinese innovative drugs evolve from early-stage value assets to core holdings recognized by global capital, and as AI becomes a core competency of domestic pharmaceutical companies, the global influence of China’s AI-driven pharmaceutical industry is rapidly accelerating—through the golden channel of weight-loss therapeutics.

 

About the "Great Power Pharmaceuticals" Column

 

The "Great Power Pharmaceuticals" column is produced by TONACEA. It focuses on the core logic behind the rise of Chinese innovative drugs, explores globalization strategies for innovative pharmaceuticals, and is dedicated to building a sustainable innovation ecosystem for China’s pharmaceutical industry. The column chronicles the stories of China’s rise amid globalization, captures key breakthroughs from following to leading, interprets national strategies, tracks cutting-edge technologies, and, through analysis of benchmark events and case studies, highlights the role of China as a major power in the pharmaceutical sector.